MENU
 JPMA
  • Directions
  • Japanese
  • About JPMA

    About JPMA: Top

    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • About Medicines

    About Medicines: Top

    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates

    Committee News Top

    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • Newsletter
  • Newsroom

    Newsroom Top

    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research
Close
 JPMA

Return to Top

  • Patients and the General Public (About Medicines)
    Patients and the General Public (About Medications) Top
    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates
    Committee News Top
    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • About JPMA
    About JPMA: Top
    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • Policies and Activities
    Policies & Activities Top
    • Business Policy, Business Plan, and Implementation Plan
    • Committee Activities
    • Convention on Biological Diversity
  • Voluntary Standards
    Voluntary Standards Top
    • Code of Conduct
    • JPMA Code of Practice
    • Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
    • Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations
    • Guidelines for the Preparation of Summaries of Product Characteristics for Prescription Drugs (Abbreviation: Preparation Guidelines)
    • Clinical Research
    • Basic Principles and Guidelines for Action on Biodiversity
    • Guidelines on Fair Competition at Meetings of the Japan Pharmaceutical Manufacturers Association
    • Agreements, Manuals, and Guidelines
  • Newsroom
    Newsroom Top
    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research  Opens in a new window
  • Social Media Policy
  • Website Terms of Use
  • Access
  • Japanese
  • Home
  • Committee Updates
  • Biopharmaceutical Committee
  • Biopharmaceutical Committee's Deliverables

Biopharmaceutical Committee Biopharmaceutical Committee's Deliverables

  • CMC Strategy Forum Japan 2025" was held.
  • Report on "BioJapan 2025" Opening Ceremony, Keynote Speech and Biopharmaceutical Seminar
  • JPMA Media Forum "Two Major Issues in Countermeasures against Infectious Diseases: Consideration of Countermeasures against Drug-Resistant Bacteria and Proper Understanding of Immunization
  • CMC Strategy Forum Japan 2024" will be held
  • Report on "BioJapan 2024" Opening Ceremony, Keynote Speech, and Biopharmaceutical Seminar
  • JPMA Media Forum "Life Course Immunization in the Era of 100 Years of Life
  • Proposals for the development of a promotion system for vaccines based on the basic strategy for the prevention of infectious diseases, from research and development to practical application and routine vaccination (excluding those related to the Pharmaceuticals and Medical Devices Law)
  • Toward early realization of new coronavirus vaccine and stable immunization system (744KB)
  • Regenerative Medicine Product: Analysis of Application Documents for Approval (Life Cycle Management Information)

Share this page

  • Post
  • Share

TOP

Site Search

  • Home
  • Committee Updates
  • Biopharmaceutical Committee
  • Biopharmaceutical Committee's Deliverables
  • JPMA PR and Communications Activities
  • Pharmaceutical Research Institute
  • List of Non-Financial Information Disclosures by Member Companies
  • STOP AMR
  • About the JPMA
  • Policies and Activities
  • Voluntary Standards
  • Global Health
  • Newsroom
  • Patients and the General Public (About Medicines)
  • Clinical Trial Information
  • Committee Updates
  • JapanesePage will open in a new window.
  •  x
  •  Facebook
  •  YouTube
  • Site Map
  • Website Terms of Use
  • Basic Policy on Information Security
  • Social Media Policy
  • Links
  • Accessibility Policy
  • PRAISE-NET Login

© Japan Pharmaceutical Manufacturers’
’ Association (JPMA). All rights reserved.

Notification

This website uses automatic translation.
The translated content may not always be fully consistent with the original Japanese content.